Human monocyte-derived dendritic cells are chemoattracted to C3a after up-regulation of the C3a receptor with interferons

Immunology

Volumn 111, Issue 4, 2004, Pages 435-443

  Gutzmer, Ralf ^a   Lisewski, Margarete ^a   Zwirner, Jörg ^b   Mommert, Susanne ^a   Diesel, Carola ^a   Wittmann, Miriam ^a   Kapp, Alexander ^a   Werfel, Thomas ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANAPHYLATOXIN; B7 ANTIGEN; CD40 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; CHEMOATTRACTANT; COMPLEMENT COMPONENT C3 RECEPTOR; COMPLEMENT COMPONENT C3A; GAMMA INTERFERON; HLA DR ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 12; PROSTAGLANDIN E2; PROTEIN P70;

ARTICLE; CELL ACTIVITY; CELL FUNCTION; CELL MIGRATION; CELLULAR DISTRIBUTION; CHEMOTAXIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; HUMAN; HUMAN CELL; HUMAN MONOCYTE DERIVED DENDRITIC CELL; IMMUNOMODULATION; INFLAMMATION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; TARGET CELL; UPREGULATION;

CELL DIVISION; CELLS, CULTURED; CHEMOTAXIS; COMPLEMENT C3A; CYTOKINES; DENDRITIC CELLS; HUMANS; INTERFERON ALFA-2A; INTERFERON TYPE II; LYMPHOCYTE ACTIVATION; MEMBRANE PROTEINS; MONOCYTES; RECEPTORS, COMPLEMENT; T-LYMPHOCYTES; UP-REGULATION;

EID: 1842684175     PISSN: 00192805     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2004.01829.x     Document Type: Article

References (55)

1. Schwartz LB, Kawahara MS, Hugli TE, Vik D, Fearon DT, Austen KF. Generation of C3a anaphylatoxin from human C3 by human mast cell tryptase. J Immunol 1983; 130:1891-5.
2. Zilow G, Sturm JA, Rother U, Kirschfink M. Complement activation and the prognostic value of C3a in patients at risk of adult respiratory distress syndrome. Clin Exp Immunol 1990; 79:151-7.
3. Kapp A, Meske-Brand S, Maly FE, Muller W. Complement activation in patients with chronic polyarthritis, measured by the level of complement fraction C3a in plasma. Z Rheumatol 1984; 43:103-5.
4. Kapp A, Wokalek H, Schopf E. Involvement of complement in psoriasis and atopic dermatitis - measurement of C3a and C5a, C3, C4 and C1 inactivator. Arch Dermatol Res 1985; 277:359-61.
5. Takematsu H, Ohkohchi K, Tagami H. Demonstration of anaphylatoxins C3a, C4a and C5a in the scales of psoriasis and inflammatory pustular dermatoses. Br J Dermatol 1986; 114:1-6.
6. Ring J, Senter T, Cornell RC, Arroyave CM, Tan EM. Complement and immunoglobulin deposits in the skin of patients with atopic dermatitis. Br J Dermatol 1978; 99:495-501.
7. Secher L, Permin H, Juhl F. Immunofluorescence of the skin in allergic diseases: an investigation of patients with contact dermatitis, allergic vasculitis and atopic dermatitis. Acta Derm Venereol 1978; 58:117-20.
8. Humbles AA, Lu B, Nilsson CA, Lilly C, Israel E, Fujiwara Y, Gerard NP, Gerard C. A role for the C3a anaphylatoxin receptor in the effector phase of asthma. Nature 2000; 406:998-1001.
9. Krug N, Tschernig T, Erpenbeck VJ, Hohlfeld JM, Koehl J. Complement factors C3a and C5a are increased in bronchoalveolar lavage fluid after segmental allergen provocation in subjects with asthma. Am J Respir Crit Care Med 2001; 164:1841-3.
10. Kildsgaard J, Hollmann TJ, Matthews KW, Bian K, Murad F, Wetsel RA. Cutting edge: targeted disruption of the C3a receptor gene demonstrates a novel protective anti-inflammatory role for C3a in endotoxin-shock. J Immunol 2000; 165:5406-9.
11. Bautsch W, Hoymann HG, Zhang Q et al. Cutting edge: guinea pigs with a natural C3a-receptor defect exhibit decreased bronchoconstriction in allergic airway disease: evidence for an involvement of the C3a anaphylatoxin in the pathogenesis of asthma. J Immunol 2000; 165:5401-5.
12. Drouin SM, Kildsgaard J, Haviland J, Zabner J, Jia HP, McCray PB Jr, Tack BF, Wetsel RA. Expression of the complement anaphylatoxin C3a and C5a receptors on bronchial epithelial and smooth muscle cells in models of sepsis and asthma. J Immunol 2001; 166:2025-32.
13. Monsinjon T, Gasque P, Chan P, Ischenko A, Brady JJ, Fontaine MC. Regulation by complement C3a and C5a anaphylatoxins of cytokine production in human umbilical vein endothelial cells. FASEB J 2003; 17:1003-14.
14. Gasque P, Chan P, Fontaine M, Ischenko A, Lamacz M, Gotze O, Morgan BP. Identification and characterization of the complement C5a anaphylatoxin receptor on human astrocytes. J Immunol 1995; 155:4882-9.
15. Zwirner J, Gotze O, Begemann G, Kapp A, Kirchhoff K, Werfel T. Evaluation of C3a receptor expression on human leucocytes by the use of novel monoclonal antibodies. Immunology 1999; 97:166-72.
16. Martin U, Bock D, Arseniev L et al. The human C3a receptor is expressed on neutrophils and monocytes, but not on B or T lymphocytes. J Exp Med 1997; 186:199-207.
17. Daffern PJ, Pfeifer PH, Ember JA, Hugli TE. C3a is a chemotaxin for human eosinophils but not for neutrophils. I. C3a stimulation of neutrophils is secondary to eosinophil activation. J Exp Med 1995; 181:2119-27.
18. el Lati SG, Dahinden CA, Church MK. Complement peptides C3a-and C5a-induced mediator release from dissociated human skin mast cells. J Invest Dermatol 1994; 102:803-6.
19. Hartmann K, Henz BM, Kruger-Krasagakes S et al. C3a and C5a stimulate chemotaxis of human mast cells. Blood 1997; 89:2863-70.
20. Nilsson G, Johnell M, Hammer CH, Tiffany HL, Nilsson K, Metcalfe DD, Siegbahn A, Murphy PM. C3a and C5a are chemotaxins for human mast cells and act through distinct receptors via a pertussis toxin-sensitive signal transduction pathway. J Immunol 1996; 157:1693-8.
21. DiScipio RG, Daffern PJ, Jagels MA, Broide DH, Sriramarao P. A comparison of C3a and C5a-mediated stable adhesion of rolling eosinophils in postcapillary venules and transendothelial migration in vitro and in vivo. J Immunol 1999; 162:1127-36.
22. Foreman KE, Glovsky MM, Warner RL, Horvath SJ, Ward PA. Comparative effect of C3a and C5a on adhesion molecule expression on neutrophils and endothelial cells. Inflammation 1996; 20:1-9.
23. Kretzschmar T, Jeromin A, Gietz C, Bautsch W, Klos A, Kohl J, Rechkemmer G, Bitter-Suermann D. Chronic myelogenous leukemia-derived basophilic granulocytes express a functional active receptor for the anaphylatoxin C3a. Eur J Immunol 1993; 23:558-61.
24. Elsner J, Oppermann M, Czech W, Dobos G, Schopf E, Norgauer J, Kapp A. C3a activates reactive oxygen radical species production and intracellular calcium transients in human eosinophils. Eur J Immunol 1994; 24:518-22.
25. Elsner J, Oppermann M, Czech W, Kapp A. C3a activates the respiratory burst in human polymorphonuclear neutrophilic leukocytes via pertussis toxin-sensitive G-proteins. Blood 1994; 83:3324-31.
26. Soruri A, Kiafard Z, Dettmer C, Riggert J, Kohl J, Zwirner J. IL-4 down-regulates anaphylatoxin receptors in monocytes and dendritic cells and impairs anaphylatoxin-induced migration in vivo. J Immunol 2003; 170:3306-14.
27. Zwirner J, Gotze O, Moser A, Sieber A, Begemann G, Kapp A, Elsner J, Werfel T. Blood- and skin-derived monocytes/macrophages respond to C3a but not to C3a (desArg) with a transient release of calcium via a pertussis toxin-sensitive signal transduction pathway. Eur J Immunol 1997; 27:2317-22.
28. Werfel T, Kirchhoff K, Wittmann M, Begemann G, Kapp A, Heidenreich F, Gotze O, Zwirner J. Activated human T lymphocytes express a functional C3a receptor. J Immunol 2000; 165:6599-605.
29. Fischer WH, Hugli TE. Regulation of B cell functions by C3a and C3a (desArg): suppression of TNF-alpha, IL-6, and the polyclonal immune response. J Immunol 1997; 159:4279-86.
30. Kacani L, Banki Z, Zwirner J, Schennach H, Bajtay Z, Erdei A, Stoiber H, Dierich MP. C5a and C5a (desArg) enhance the susceptibility of monocyte-derived macrophages to HIV infection. J Immunol 2001; 166:3410-5.
31. Zwirner J, Werfel T, Wilken HC, Theile E, Gotze O. Anaphylatoxin C3a but not C3a (desArg) is a chemotaxin for the mouse macrophage cell line J774. Eur J Immunol 1998; 28:1570-7.
32. + dendritic cells derived from human skin. Immunology 2001; 103:210-7.
33. Gutzmer R, Langer K, Lisewski M, Riekborn D, Kapp A, Werfel T. Expression and function of histamine receptors H1 and H2 on human monocyte derived dendritic cells. J Allergy Clin Immunol 2002; 109:524-31.
34. Pfafl MW. A new mathematical model for relative quantification in real-time RT PCR. Nucleic Acid Res 2001; 29:E45.
35. Elsner J, Dichmann S, Dobos GJ, Kapp A. Actin polymerization in human eosinophils, unlike human neutrophils, depends on intracellular calcium mobilization. J Cell Physiol 1996; 167:548-55.
36. Howard TH, Meyer WH. Chemotactic peptide modulation of actin assembly and locomotion in neutrophils. J Cell Biol 1984; 98:1265-71.
37. Schroder JM, Mrowietz U, Morita E, Christophers E. Purification and partial biochemical characterization of a human monocyte-derived, neutrophil-activating peptide that lacks interleukin 1 activity. J Immunol 1987; 139:3474-83.
38. Burg M, Martin U, Bock D, Rheinheimer C, Kohl J, Bautsch W, Klos A. Differential regulation of the C3a and C5a receptors (CD88) by IFN-gamma and PMA in U937 cells and related myeloblastic cell lines. J Immunol 1996; 157:5574-81.
39. Basset-Seguin N, Caughman SW, Yancey KB. A-431 cells and human keratinocytes synthesize and secrete the third component of complement. J Invest Dermatol 1990; 95:621-5.
40. Terui T, Ishii K, Ozawa M, Tabata N, Kato T, Tagami H. C3 production of cultured human epidermal keratinocytes is enhanced by IFNgamma and TNFalpha through different pathways. J Invest Dermatol 1997; 108:62-7.
41. Terui T, Kato T, Tagami H. Complement activation by stratum corneum through the antibody- independent alternative pathway. Dermatologica 1989; 179:123.
42. Fischer WH, Jagels MA, Hugli TE. Regulation of IL-6 synthesis in human peripheral blood mononuclear cells by C3a and C3a (desArg). J Immunol 1999; 162:453-9.
43. Takabayashi T, Vannier E, Clark BD, Margolis NH, Dinarello CA, Burke JF, Gelfand JA. A new biologic role for C3a and C3a desArg: regulation of TNF-alpha and IL-I beta synthesis. J Immunol 1996; 156:3455-60.
44. Takabayashi T, Vannier E, Burke JF, Tompkins RG, Gelfand JA, Clark BD. Both C3a and C3a (desArg) regulate interleukin-6 synthesis in human peripheral blood mononuclear cells. J Infect Dis 1998; 177:1622-8.
45. Hugli TE. Structure and function of C3a anaphylatoxin. Curr Top Microbiol Immunol 1990; 153:181-208.
46. Wilken HC, Gotze O, Werfel T, Zwirner J. C3a (desArg) does not bind to and signal through the human C3a receptor. Immunol Lett 1999; 67:141-5.
47. Kalant D, Cain SA, Maslowska M, Sniderman AD, Cianflone K, Monk PN. The chemoattractant receptor-like protein C5L2 binds the C3a des-Arg77/acylation- stimulating protein. J Biol Chem 2003; 278:11123-9.
48. Ohno M, Hirata T, Enomoto M, Araki T, Ishimaru H, Takahashi TA. A putative chemoattractant receptor, C5L2, is expressed in granulocyte and immature dendritic cells, but not in mature dendritic cells. Mol Immunol 2000; 37:407-12.
49. Samson M, Edinger AL, Stordeur P et al. ChemR23, a putative chemoattractant receptor, is expressed in monocyte-derived dendritic cells and macrophages and is a coreceptor for SIV and some primary HIV-1 strains. Eur J Immunol 1998; 28:1689-700.
50. Drouin SM, Corry DB, Kildsgaard J, Wetsel RA. Cutting edge: the absence of C3 demonstrates a role for complement in Th2 effector functions in a murine model of pulmonary allergy. J Immunol 2001; 167:4141-5.
51. Drouin SM, Corry DB, Hollman TJ, Kildsgaard J, Wetsel RA. Absence of the complement anaphylatoxin C3a receptor suppresses Th2 effector functions in a murine model of pulmonary allergy. J Immunol 2002; 169:5926-33.
52. Morgan EL, Weigle WO, Hugli TE. Anaphylatoxin-mediated regulation of the immune response. I. C3a- mediated suppression of human and murine humoral immune responses. J Exp Med 1982; 155:1412-26.
53. + suppressor T cell. J Immunol 1985; 134:51-7.
54. Kalinski P, Hilkens CM, Wierenga EA, Kapsenberg ML. T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. Immunol Today 1999; 20:561-7.
55. Morgan EL. The role of prostaglandins in C3a-mediated suppression of human in vitro polyclonal antibody responses. Clin Immunol Immunopathol 1987; 44:1-11.